Internal Medicine, Endocrinology, Diabetes, & Metabolism · Saint Louis, MO
NPI
1205816790
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
10004 Kennerly Rd, Suite 160b
Saint Louis, MO, 63128
Phone (314) 842-1588
Groups this clinician bills Medicare through
Medicare paid, 2024
$269K
33,996 services
Medicare patients, 2024
629
Average age 73
Drug cost, 2024
$4.4M
8,085 prescriptions
Company payments, 2025
$2,815
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by K. G Thampy was code J1071 (injection, testosterone cypionate, 1 mg), 25,075 times for 11 patients. In total K. G Thampy billed 33,996 services in 39 codes, and Medicare paid $269K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-04-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1071 Injection, testosterone cypionate, 1 mg | Office | 25,075 | 11 | $0.02 | $450 |
| J0897 Injection, denosumab, 1 mg | Office | 2,940 | 31 | $20.07 | $59K |
| 99214 Office E&M - Established | Office | 1,072 | 432 | $83.98 | $90K |
| 95251 Test - Miscellaneous | Office | 867 | 293 | $23.32 | $20K |
| 96372 Injection Administration | Office | 346 | 50 | $9.61 | $3,325 |
| 99213 Office E&M - Established | Office | 333 | 224 | $55.71 | $19K |
| 82947 Clinical Chemistry | Office | 244 | 153 | $3.82 | $932 |
| 83036 Blood Count | Office | 238 | 151 | $9.44 | $2,247 |
| G0008 Administration of influenza virus vaccine | Office | 102 | 102 | $31.21 | $3,183 |
| 76536 Ultrasound - Nonspecific | Office | 99 | 95 | $68.71 | $6,802 |
| 90662 Vaccine Product | Office | 90 | 90 | $81.82 | $7,364 |
| 99215 Office E&M - Established | Office | 71 | 57 | $116.34 | $8,260 |
| 99232 Hospital E&M - Subsequent | Facility | 63 | 31 | $56.35 | $3,550 |
| 99222 Hospital E&M - Initial | Facility | 60 | 52 | $90.13 | $5,408 |
| 95249 Test - Miscellaneous | Office | 45 | 44 | $43.13 | $1,941 |
By year: 2022 $383K for 33,494 services; 2023 $328K for 34,355 services; 2024 $269K for 33,996 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82947 Clinical Chemistry | 244 | 153 | $3.82 | $932 |
| 83036 Blood Count | 238 | 151 | $9.44 | $2,247 |
Medicare prescription drug claims, 2024
In 2024, the drug K. G Thampy prescribed most often to Medicare patients was Ozempic (Semaglutide), with 887 prescriptions and refills. In total K. G Thampy wrote 8,085 Medicare prescriptions that cost $4.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 887 | 1,491 | 252 | $1.4M |
| Levothyroxine Sodium Generic | 823 | 2,216 | 232 | $11K |
| Tresiba Flextouch U-100 Insulin Degludec | 671 | 1,469 | 261 | $717K |
| Vitamin D2 Ergocalciferol (Vitamin D2) | 597 | 1,676 | 182 | $5,179 |
| Synthroid Levothyroxine Sodium | 382 | 978 | 106 | $42K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 369 | 976 | 167 | $67K |
| Metformin Hcl Er Metformin Hcl | 349 | 948 | 99 | $5,451 |
| Fiasp Flextouch Insulin Aspart (Niacinamide) | 333 | 617 | 122 | $475K |
| Tresiba Flextouch U-200 Insulin Degludec | 293 | 624 | 88 | $486K |
| Humalog Kwikpen U-100 Insulin Lispro | 214 | 455 | 87 | $99K |
| Cyanocobalamin Injection Cyanocobalamin (Vitamin B-12) | 210 | 576 | 68 | $4,827 |
| Novolog Flexpen Insulin Aspart | 208 | 413 | 85 | $90K |
| Metformin Hcl Generic | 177 | 512 | 52 | $1,517 |
| Ultra-Fine Nano Pen Needle Pen Needle, Diabetic | 170 | 351 | 70 | $20K |
| Calcitriol Generic | 131 | 284 | 47 | $3,684 |
Brand drugs: 4,403 claims; generic drugs: 2,757 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid K. G Thampy $2,815 ($2,815 in general payments such as food, travel and fees) from 16 companies. The largest payer was Medtronic, Inc. with $565.
| Company | Payments | Amount |
|---|---|---|
| Medtronic, Inc. MDT | 9 | $565 |
| Abbvie Inc. ABBV | 13 | $284 |
| Dexcom, Inc. DXCM | 17 | $269 |
| Abbott Laboratories ABT | 20 | $239 |
| Madrigal Pharmaceuticals MDGL | 5 | $214 |
| Globus Medical, Inc. GMED | 11 | $201 |
| Sequel Med Tech, LLC | 12 | $197 |
| Sanofi-Aventis U.S. LLC SNY | 4 | $193 |
| Neurocrine BioSciences, Inc. NBIX | 3 | $166 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 4 | $139 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.